(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual revenue growth rate of 7.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Dianthus Therapeutics's revenue in 2024 is $2,255,000.On average, 4 Wall Street analysts forecast DNTH's revenue for 2024 to be $67,063,537, with the lowest DNTH revenue forecast at $25,534,038, and the highest DNTH revenue forecast at $107,125,562. On average, 3 Wall Street analysts forecast DNTH's revenue for 2025 to be $76,690,162, with the lowest DNTH revenue forecast at $53,709,528, and the highest DNTH revenue forecast at $117,691,371.
In 2026, DNTH is forecast to generate $80,681,690 in revenue, with the lowest revenue forecast at $53,650,829 and the highest revenue forecast at $129,724,653.